QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process What is securities trading DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights.
- Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins.
- Analytical instruments company Thermo Fisher Scientific Inc. reported Wednesday first-quarter profit and revenue that topped expectations, as revenue beats in its laboratory products, specialty diagnostics and life scienc…
- Working closely with the forensic community, Verogen places exceptional value on flexible, scalable solutions that deliver reliable results.
This tailored approach not only enhances patient outcomes, but also contributes to cost savings within the healthcare system. Managing CMV disease can be financially burdensome, and proactive testing helps to alleviate this burden by providing targeted care for those at risk. In early 2023, QIAGEN’s emissions reduction targets were validated by the Science Based Targets initiative (SBTi), positioning it among the few companies best stocks to day trade in its sector with a verified net-zero science-based target. The company has committed to achieving net-zero greenhouse gas (GHG) emissions by 2050, using 2020 as the base year. In 2022, QIAGEN made significant strides, reporting a 20% decrease in Scope 1 and 2 emissions and a 13% reduction in Scope 3 emissions compared to 2021. QIAGEN also surpassed its target for a 9% reduction in plastic usage, achieving a 16.5% decrease.
After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. First-of-its-kind systematic review on the clinical relevance of test values from the QuantiFERON-TB Gold Plus TB1 and TB2 blood collection tubes has been published // Study including 4,050 subjects h…
Email Alerts
The QIAwave DNA/RNA Mini Kit allows for simultaneous purification of genomic DNA and total RNA from each cell or tissue sample, with the purified DNA and RNA eluted separately. Qiagen NV (QGEN) stock is lower by -3.99% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives QGEN stock a score of 21 out of a possible 100. A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.
AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome… To help clinicians determine the right dosage of immunosuppressive drugs to prevent both organ rejection and post-transplant infections, the TSN recommends the use of QuantiFERON Monitor before and after surgery. Testing before a kidney transplant allows for corrective measures for patients found to have weak immune systems, while post-surgical testing would aid clinicians in adjusting the regime of immunosuppressive medication that is crucial after any transplant.
- In 2022, QIAGEN continued to provide access to life-saving Sample to Insight solutions to communities worldwide.
- Multiplex amplification for human ID, with CODIS and European standard markers.
- QIAGEN’s ESG performance has also been acknowledged by other independent rating agencies.
- A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.
QIAGEN currently expects about $20 million of sales from the Verogen portfolio in 2023, building on about $5 million of sales for QIAGEN in 2022 from the distribution agreement. Due to planned investments for commercialization and portfolio development, the transaction is expected to be dilutive to full-year 2023 adjusted EPS by about $0.03 per share and neutral to adjusted EPS in 2024. Human identification DNA techniques have evolved greatly over the past few decades, helping to meet huge challenges like in the aftermaths of wars and natural disasters, as well as to support advances in criminal justice. As just one example, the International Commission on Missing Persons in the Netherlands to date has profiled more than 44,000 bone samples and made more than 18,000 identifications – all processed using QIAGEN chemistry and kits. For over two decades, QCI Interpret has combined the accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to enable high-confidence variant interpretation and reporting. QIAGEN has been recognized for its ongoing commitment to sustainability and responsible business practices with a recent ESG rating upgrade from ISS-ESG.
By the end of 2022, the top 95% of suppliers by expenditure had signed the policy, and all suppliers that accept purchase orders from 2023 need to agree to comply with the policy. In 2022, 95% of QIAGEN’s overall purchasing volume came from OECD countries. Analytical instruments company Thermo Fisher Scientific Inc. reported Wednesday first-quarter profit and revenue that topped expectations, as revenue beats in its laboratory products, specialty diagnostics and life scienc… In 2018, QIAGEN transferred its listing to New York Stock Exchange.[27] In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform. Verogen, a privately held company founded in 2017 and based in San Diego, supports the global human identification community with NGS tools and professional services to help resolve criminal and missing-persons cases.
QIAGEN announces expansion of Supervisory Board
With an incidence rate ranging from 8% to 32%1, CMV disease stands as the most prevalent infectious complication following kidney transplant procedures. The required immunosuppressive medications, essential for preventing organ rejection, weaken the patient’s immune system, making it more challenging to control viral infections. Post-transplant CMV poses the risk of causing severe complications such as direct harm to the transplanted organ, graft rejection or dysfunction, and heightened susceptibility to other infections. QIAGEN is aiming to reduce its plastic footprint, in particular by replacing expanded polystyrene (EPS) boxes for cooled shipments with recyclable alternatives made of straw and other forms of plastic packaging with more eco-friendly alternatives.
Can Iqvia Holdings Inc (IQV) Stock Rise to the Top of Healthcare Sector Friday?
The products feature fewer components, waste tubes made from 100% recycled plastic, and suitable buffer concentrates in smaller bottles. More compact kits and new ways of packing them reduce the amount of cardboard needed for packaging. QCI Interpret continuously expands its global footprint and is adopted by an increasing number of programs and institutions. For example earlier this year, the Danish National Genome Center selected QCI Interpret for variant interpretation in oncology genome sequencing.
Thermo Fisher Is Buying Qiagen for $11.5 Billion. It’s a ‘Home Run’ Deal.
It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. 52 week high is the highest price of a stock in the past 52 weeks, or one year. All market data (will open in new tab) is provided by Barchart Solutions.
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business. News, testing solutions and stories covering global efforts in the fight against COVID-19.
When an infection-specific antigen is combined with the blood, rapid re-stimulation of antigen-specific T-cells occurs, leading to the secretion of interferon-gamma (IFN-γ), which can be measured as a marker of an immune response. CMV immune response monitoring enables healthcare providers to pinpoint patients with higher risks of developing complications, thereby allowing them to administer suitable treatments and mitigate how to read forex charts the chances of full-blown CMV disease and transplant loss. As a result, the TSN advises QuantiFERON-CMV to be used for nationwide immune response monitoring the year after surgery. Patients testing positive with an adequate immune response to the virus should be released from prophylactic treatment after three months, while those testing negative, and more at risk to CMV disease, should be monitored for up to six months.
QIAGEN strives to ensure that its suppliers and customers share the same values and continues to promote responsible and ethical business conduct combined with respect for human rights as a fundamental value. Qiagen NV raised its outlook for 2020 and 2021 on Tuesday after increasing production amid the coronavirus pandemic. The Germany-based provider of sample and assay technologies now expects net sales to grow by at least 32%… QIAwave kits use up to 62% less plastic and up to 58% less cardboard than QIAGEN’s most popular kits for extracting DNA, RNA and plasmid DNA from samples, making them a more sustainable choice for laboratories. The QIAwave product line is the first to use both recycled plastics and space-saving chemical concentrates.
A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included. Qiagen NV lost about one-fifth of its market value on Thursday after the Dutch biotechnology company said earlier this week that it would focus on its stand-alone business strategy, rejecting possible suitors. Shares of Mirati Therapeutics Inc. were up about 3% in premarket trading on Tuesday, the day after the company said it received an accelerated approval from the Food and Drug Administration for a treatment for some people… In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option.
The software will be used at testing sites throughout Denmark and support the nationwide initiative to offer sequencing-based solutions for cancer patients. The report showcases QIAGEN’s strategic approach towards sustainable transformation, including its ambitious emissions reduction goals, diversity and inclusion initiatives, and efforts to expand global access to vital medical testing. QIAGEN recently completed the full acquisition of Verogen for $150 million in cash paid from existing reserves.
At the core of this strategy is a focus on five pillars of growth which are built on the company’s leadership in sample technologies, the first step in any laboratory process. QIAGEN – which in the late 1990s launched the first commercial kits to purify DNA from forensic casework samples – already has a leading position in the HID / forensics market. QIAGEN’s sample collection and preparation kits, genetic testing analysis, and workflow automation products are used around the world by forensic science laboratories and criminal investigators. Reducing its plastic footprint is just one aspect of QIAGEN’s sustainability initiatives.
